Review demonstrates how FAP-targeted CAR T-cell therapy overcomes solid tumor immunosuppression and integrates with radioligands, highlighting expanding immunotheranostic applications.
Key Points
To summarize the development and therapeutic potential of fibroblast activation protein (FAP)-directed CAR T-cell platforms in solid tumors, tracing their progression toward modular and immunotheranostic designs.
Reviewed preclinical and clinical literature concerning FAP-targeted CAR T-cell engineering and stroma-directed antitumor strategies.
Analyzed adapter-mediated CAR T-cell systems and FAP inhibitor (FAPI) radiotracers used to integrate cellular immunotherapy with targeted radioligand delivery.
Targeting FAP on cancer-associated fibroblasts effectively remodels the immunosuppressive tumor microenvironment, supporting the clinical translation of two CAR T-cell candidates.
Adapter CAR T-cell platforms provide controllable, on-demand activation to improve therapeutic safety and flexibility against solid tumors.
Merging modular CAR T-cell systems with FAP-targeted radioligands forms a unified immunotheranostic approach combining tumor imaging and dual-modality cytotoxicity.